Cambridge Healthtech Institute’s Inaugural

Small Molecules for Immunology & Oncology

Drug Discovery against Molecular Targets in Inflammation, Autoimmunity and Cancer

April 15-16, 2020



Cambridge Healthtech Institute’s Inaugural Small Molecules for Immunology & Oncology conference is a merging of our long-standing Inflammation Inhibitors meeting with our more recent Small Molecules for Cancer Immunotherapy conference in recognition of the commonalities among the drug targets in both fields from the standpoint of a medicinal chemist.

Evidence is mounting that autoimmunity/inflammation versus cancer can be considered two sides of the same coin. Inflammation arises when the immune system is overactive whereas cancer is largely a result of an underactive or subverted immune system. Hence medicinal chemists often design drugs against the same target for these seemingly opposite diseases: developing antagonists to inhibit autoimmunity/inflammation or agonists for the same molecular target to activate the immune system against cancer. We hope you can join fellow chemists at this event to share strategies, successes and challenges in discovering and optimizing drug candidates that have the potential to be orally bioavailable modulators of the immune system be it for cancer or other diseases.


Preliminary Agenda

STING AND OTHER INNATE IMMUNITY TARGETS

Characterization of Novel STING Ligands

Gottfried Schroeder, PhD, Senior Scientist, Department of Pharmacology, Merck Research Labs Boston

Discovery of STING Agonist with Systemic Anti-Tumor Response

Scott Pesiridis, PhD, Associate Fellow, Scientific Leader - Discovery Biology, GlaxoSmithKline

NUCLEAR RECEPTORS AND OTHER INTRACELLULAR IMMUNO-TARGETS

Discovery and Early Clinical Trial Results of BIIB068: a Selective, Potent, Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK)

Bin Ma, PhD, Senior Scientist, Medicinal Chemistry, Biogen

Discovery and Development of AUR101: an ROR Gamma Inverse Agonist for the Treatment of Psoriasis

Murali Ramachandra, PhD, CEO, Aurigene Discovery Technologies Limited

Regulation of Inflammatory Cell Death Signaling by RIP Kinases

Domagoj Vucic, PhD, Principal Scientist, Early Discovery Biology, Genentech

Small-Molecule TEAD-Yap Covalent Antagonists

Samy Meroueh, PhD, Associate Professor, Biochemistry & Molecular Biology, Indiana University

Targeting Vps34 Induces a Proinflammatory Microenvironment Resulting in Tumor Growth Inhibition and Sensitization to PD-1/ PD-L1 Blockade

Jenny Viklund, Director, Protein Science & Drug Design, Sprint Biosciences


CELL SURFACE I&O TARGETS FOR SMALL MOLECULES

Targeting av Integrins for Fibrosis

Katrina Leftharis, PhD, Vice President, Chemistry, Pliant


* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean


Update History
2019/11/25
Sponsor updated
2019/10/31
Agenda,Sponsor updated